Kyoto Drug Discovery and Development Co., Ltd., a clinical stage pharmaceutical company developing novel neuroprotective therapies, today announced that the phase clinical trial assessing the efficacy and safety of KUS in patients with central retinal artery occlusion (CRAO)
Source: kyoto drug